Reply to “Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings”

We thank Dr. Martin and colleagues for their interest in our study and for presenting additional data on the usage of glecaprevir, pibrentasvir  + sofosbuvir + ribavirin (G/P+SOF+RBV) for the rescue treatment of patients with chronic hepatitis C who failed to voxilaprevir, velpatasvir, sofosbuvir (VOX/VEL/SOF) as retreatment.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research